The Campaign for Sustainable Rx Pricing

A coalition of organizations working on market-based solutions to drug pricing.

Based in DC

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $2.6M in lobbying spend across 33 quarterly filings, The Campaign for Sustainable Rx Pricing is a significant lobbying presence. They deploy 30 individual lobbyists Their lobbying covers 6 issue areas. Active from 2018 to 2025.

$2.6M
Total Spend
8
Years Active
1
Firms Hired
30
Lobbyists Deployed
6
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$320K
2019$320K
2020$520K
2021$440K
2022$220K
2023$200K
2024$230K
2025$360K

Issues Lobbied

Health IssuesMedicare/MedicaidPharmacyBudget/AppropriationsCopyright/PatentTrade

Lobbying Firms

Mehlman Consulting, INC.

Lobbyists

Bruce MehlmanDavid CastagnettiDean RosenConstantine HingsonDavid ThomasElise Finley PickeringSohini GuptaSage EastmanLauren AronsonMichael RobinsonMichael CollinsSteve HaroHelen TolarNichole DistefanoMckenzie BricePaul ThornellStephen CoteAlexander PerkinsVictoria FloodRosemary GutierrezZachary MalloveCaitlin Van SantLisa GoldmanAlyene MlinarErica ChabotAnnie WolfNaveen ParmarJon AdameJoseph BrownEarl Flood

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Pharmacy, Budget/Appropriations, Copyright/Patent and 1 more

  • •Prescription drug pricing.
  • •S. 974 - CREATES Act.
  • •S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
  • •H.R. 2051 - FAST Generics Act of 2017.
  • •Medicare Part D Biosimilars
  • •Prescription drug pricing.
  • •Medicare Part D Biosimilars.
  • •H.R. 1892 - The Bipartisan Budget Act of 2018, Omnibus
  • •Prescription drug pricing.
  • •S. 974 - CREATES Act.
  • •S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
  • •H.R. 2051 - FAST Generics Act of 2017
  • •Medicare Part D Biosimilars.
  • •H.R. 1892 - The Bipartisan Budget Act of 2018, Omnibus

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders
🏭 Tech Lobbying
Industry overview and top spenders

Related Investigations

Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.

Similar Clients

GSK (FKA Glaxosmithkline INC.)
$39.9M total spend
National Organization for Rare Disorders INC (Nord)
$2.1M total spend
Siemens Healthineers (FKA Varian Medical Systems, INC.)
$1.9M total spend
Association for Accessible Medicines (Formerly - Generic Pharmaceutical Assn)
$1.3M total spend
Campaign for Sustainable Drug Pricing
$580K total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.